This variant lies in a transcriptional enhancer that binds AP-1 (ref. 20) with allele-preference for the RCC risk allele, A. We show that the enhancer acts on several genes in the region, with the strongest effect on BHLHE41, whose effect is complex and promotes renal cancer formation and progression. This evidence concerns the gene FOS and renal carcinoma.